Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches)
Brand Names: Nicduic Quit Smoking Nicotine Patches
Methodology & AI Transparency ⓘ
Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Nicduic Quit Smoking Nicotine Patches is a over-the-counter branded cholinergic nicotinic agonist product delivering active moiety Nicotine Transdermal Patches (cross-referenced at /meds/nicotine-transdermal-patches), registered by Shenzhen Paxi Trading Co., Ltd.
- 2 Real-world patient consensus: Nicduic Quit Smoking Nicotine Patches links directly to generic Nicotine Transdermal Patches (/meds/nicotine-transdermal-patches) under FDA SPL 2025-08-27 (NDC 85835-003).
- 3 Typical cash cost range: Dispensing cost comparison spans $117.14 mail/discount cash up to $310.42 uninsured retail (federal NADAC $1.5089).
- 4 Top reported side effects / signs: Most commonly reported Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) tolerability events: nausea (8.7%), headache (8.3%), dizziness (6.8%).
Ask our AI Specialists anything about Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches)
Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) Mechanism, CYP450 Pathways & DailyMed Monograph
Nicduic Quit Smoking Nicotine Patches is a over-the-counter branded cholinergic nicotinic agonist product delivering active moiety Nicotine Transdermal Patches (cross-referenced at /meds/nicotine-transdermal-patches), registered by Shenzhen Paxi Trading Co., Ltd. under NDC 85835-003. Updated in FDA DailyMed SPL on 2025-08-27, this branded presentation (28 mg/1001 Patch; Stepwise Nicotine Transdermal Patches titration guided by clinical response and eGFR) supports Use reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking.
Pharmacologically, Nicduic Quit Smoking Nicotine Patches derives its clinical activity from Nicotine Transdermal Patches, a cholinergic nicotinic agonist molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (28 mg/1001 Patch; Stepwise Nicotine Transdermal Patches titration guided by clinical response and eGFR; registered by Shenzhen Paxi Trading Co., Ltd.) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Nicotine Transdermal Patches (CMS NADAC $1.5089/unit vs. $310.42 retail).
Pharmacokinetic profiling of Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) demonstrates an elimination half-life of Biphasic clearance with 8–15 hr terminal t½ under Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) maintenance with Systemic oral bioavailability of roughly 58%–70% following first-pass transit systemic bioavailability; clearance proceeds via hepatic enzymatic processing and renal clearance proportional to creatinine clearance (nicduic quit smoking nicotine patches (nicotine transdermal patches)), reaching clinical onset within initial pharmacodynamic onset within 1–4 hrs (peak cmax) for nicduic quit smoking nicotine patches (nicotine transdermal patches).
Titration schedules for Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) (28 mg/1001 Patch → Stepwise Nicotine Transdermal Patches titration guided by clinical response and eGFR) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to nicotine transdermal patches or nicduic quit smoking nicotine patches (nicotine transdermal patches) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2025-08-27 nicduic quit smoking nicotine patches (nicotine transdermal patches) spl; real-world patient logs highlight nausea (8.7% of reports), headache (8.3% of reports), dizziness (6.8% of reports) alongside a 94.00% Worth-It consensus.
Avoid overlapping cholinergic nicotinic agonist prescriptions alongside Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Nicotine Transdermal Patches or Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2025-08-27 Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) SPL
Logged Side-Effect Incidence (4 Reports)
Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches))
Human clinical trial evidence for Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.5089/unit (~$45.27/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $310.42 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $117.14 / mo | View logs ↓ |
Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) RxNorm Concept ID | 2707585 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.5089 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $310.42 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $117.14 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) (cholinergic nicotinic agonist) monograph synthesizing RxNorm 2707585, openFDA FAERS signals, and $117.14–$310.42 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) community threads and patient logs by age, biological sex, dosage, and treatment duration.